Urinary Tract Infection News and Research

RSS

Urinary tract infections are a serious health problem affecting millions of people each year. Infections of the urinary tract are the second most common type of infection in the body. Urinary tract infections (UTIs) account for about 8.3 million doctor visits each year.* Women are especially prone to UTIs for reasons that are not yet well understood. One woman in five develops a UTI during her lifetime. UTIs in men are not as common as in women but can be very serious when they do occur.

Non-drug approaches work better in people with Alzheimer's disease, dementia

Doctors write millions of prescriptions a year for drugs to calm the behavior of people with Alzheimer's disease and other types of dementia. But non-drug approaches actually work better, and carry far fewer risks, experts conclude in a new report.

4 Mar 2015

Majority of ACS NSQIP hospitals improve surgical outcomes over time

The majority of hospitals participating in the American College of Surgeons National Surgical Quality Improvement Project improve surgical outcomes over time, and improvement continues with each year that hospitals participate in the program, according to a new study published online today in Annals of Surgery.

28 Feb 2015

Signostics gets FDA 510k clearance for handheld bladder scanner

Medical device company, Signostics, announced today it has clearance from the U.S. Food and Drug Administration to launch the SignosRT Bladder, the company’s new hand-held bladder scanner.

15 Jan 2015

Antibiotic resistance remains a serious health problem in Australia, warns NPS MedicineWise

In light of a major breakthrough in the quest to find new antibiotics with the discovery of teixobactin, NPS MedicineWise warns that antibiotic resistance in Australia remains a serious health problem we all need to work to address.

14 Jan 2015

Researchers identify way to assess women at increased risk for UTI after pelvic-floor surgery

Researchers at Loyola University Chicago Stritch School of Medicine may have identified a way to assess who is at risk for developing a urinary tract infection (UTI) following pelvic-floor surgery.

11 Dec 2014

Alport syndrome: an interview with Dr Paul Grint, CMO, Regulus

Alport Syndrome was first described by a physician called Cecil Alport, back in the late 1920s. It's a genetic disease that affects a certain type of collagen involved in the functioning of the kidney, the ear, and the eye.

1 Dec 2014

NPS MedicineWise Reducing Antibiotic Resistance program focuses on urinary tract infections

The next phase of the NPS MedicineWise Reducing Antibiotic Resistance program for health professionals has launched today focused on the complex topic of managing urinary tract infections (UTIs).

21 Nov 2014

Sanofi, Genzyme announce FDA approval of Lemtrada for treatment of relapsing forms of MS

Sanofi and its subsidiary Genzyme announced today that the U.S. Food and Drug Administration has approved Lemtrada (alemtuzumab) for the treatment of patients with relapsing forms of multiple sclerosis (MS). Because of its safety profile, the use of Lemtrada should generally be reserved for patients who have had an inadequate response to two or more drugs indicated for the treatment of MS.

17 Nov 2014

Boehringer Ingelheim announces availability of Striverdi Respimat Inhalation Spray 5 mcg in the U.S.

Boehringer Ingelheim today announced that Striverdi Respimat (olodaterol) Inhalation Spray 5 mcg is now available by prescription in pharmacies across the United States.

8 Oct 2014

Phase 3 COU-AA-302 results show ZYTIGA plus prednisone prolongs overall survival in men with chemotherapy-naive mCRPC

A final analysis of the Phase 3 COU-AA-302 trial presented today at the European Society for Medical Oncology (ESMO) 2014 Congress in Madrid, Spain showed that ZYTIGA® (abiraterone acetate) plus prednisone significantly prolonged overall survival (OS), compared to an active control of placebo plus prednisone, in men with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC).

30 Sep 2014

Common type of hospital-associated infections can be prevented with vaccine

The most common type of hospital-associated infection may be preventable with a vaccine, new research in mice suggests.

18 Sep 2014

No added benefit determined from Mirabegron for mortality, morbidity and quality of life

Mirabegron (trade name: Betmiga) has been approved since December 2012 for the treatment of adults with overactive bladder.

3 Sep 2014

Drugs plus biofeedback show promise for dysfunctional voiding

Research shows that the use of α1-blockers in combination with uroflowmetry biofeedback is more effective than either treatment alone for improving urinary symptoms and quality of life in women with dysfunctional voiding and recurrent urinary tract infection.

1 Sep 2014

Jardiance (empagliflozin) tablets now available in U.S. for people with diabetes

Jardiance (empagliflozin) tablets are now available by prescription in pharmacies across the United States, including Walgreens, Rite Aid, Kroger and many other leading chain and independent retailers, according to Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company.

26 Aug 2014

Risk of urinary tract infections after prostate biopsy highest in men with prior infections

Risk of Urinary Tract Infections after Prostate Biopsy Highest in Men with Prior Infections or Significant Comorbidities, Report Swedish Researchers in The Journal Of Urology®

21 Aug 2014

Immunosignaturing holds promise for accurate diagnosis of Valley Fever

On July 5, 2011, a massive wall of dust, ("haboob," in Arabic), blanketed Phoenix, Arizona, creating an awesome spectacle, (or stubborn nuisance, depending on your perspective). Dust storms are a common occurrence in the arid desert environments of the American Southwest.

23 Jul 2014

Sixteen cores better than 12 for prostate cancer detection

Sixteen-core prostate biopsy has a slightly higher cancer detection rate than 12-core biopsy, but with a similar safety profile and no increased detection of clinically insignificant tumours, study findings show.

21 Jul 2014

UCB, Dermira enter into licensing agreement for development, commercialization of Cimzia

UCB, a global biopharmaceutical leader, and Dermira, Inc., a privately held US-based dermatology company, announced today that they have entered into an exclusive licensing agreement for the development and future commercialization of Cimzia (certolizumab pegol) in dermatology.

3 Jul 2014

Vanda’s HETLIOZ MAA for Non-24-Hour Sleep-Wake Disorder accepted for evaluation by the EMA

Vanda Pharmaceuticals Inc. announced today that its Marketing Authorization Application (MAA) for oral HETLIOZ™ (tasimelteon) capsules has been accepted for evaluation by the European Medicines Agency (EMA) for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).

3 Jun 2014

Findings explain why women with bladder cancer are often diagnosed at later stage than men

Women with blood in their urine (hematuria) were less than half as likely as men with the same issue to be referred to a urologist for further tests, according to a new Vanderbilt University study.

28 May 2014